A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, a trial has found.

Almost one in five patients with advanced melanoma survived for five years after receiving the innovative treatment ...

Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- ...

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to a State ...